Johnson & Johnson reports two-year ICOTYDE data in difficult-to-treat plaque psoriasis

Johnson & Johnson said on October 2, 2026 that it had released new two-year data from the Phase 3 ICONIC-TOTAL study of ICOTYDE (icotrokinra) in adults and adolescents with plaque psoriasis affecting high-impact sites of the body. The results were shared as an oral presentation at the European Academy of Dermatology and Venereology Congress 2026.

The company said rates of clear or almost clear skin, measured by the Investigator's Global Assessment, rose from 57% at Week 16 to 67% at Week 24 and 70% at Week 112. At Week 112, 63% of patients with psoriasis of the hands and/or feet achieved a score of 0 on the hand and/or foot Physician's Global Assessment.

Johnson & Johnson said safety findings through Week 112 were consistent with the established safety profile of ICOTYDE, with no new safety signals identified. Mean improvement in nail psoriasis rose from 33% at Week 16 to 62% at Week 52 and 71% at Week 112.

ICOTYDE is approved in the U.S. for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. It is also approved in Europe, Japan and China for adults and adolescents with psoriasis.